DELZICOL delayed-release capsules are indicated for1:
Adults: The recommended dosage is two DELZICOL 400 mg capsules three times daily (total daily dose of 2.4 g/d), with or without food, for a duration of 6 weeks
Pediatric patients 5 years of age and older: Total daily dose is weight-based up to a maximum of 2.4 g/d, with or without food, divided into two daily doses for a duration of 6 weeks
*Improved was defined as reduction in the physician’s global assessment (PGA) score and in at least one other component score, with no score increased in severity.3
†Remission was defined as complete resolution of all symptoms, with all assessment scores determined to be 0.3
‡A 6-week, multicenter, double-blind, placebo-controlled, randomized study of 158 patients with mildly to moderately active UC. The primary endpoint was treatment outcome (patients in remission, improved, maintained, or worsened) at 6 weeks. Treatment outcome was based on the following assessments: stool frequency, rectal bleeding, sigmoidoscopic findings, patient’s functional assessment, and PGA.3
§A 6-month, double-blind, randomized, multicenter, placebo-controlled trial of 264 patients with UC in remission at study entry. The primary endpoint was treatment outcome—either success, defined as maintenance of remission (as indicated by sigmoidoscopic evaluation) at the 6-month study visit, or failure, defined as sigmoidoscopic relapse at any time during the study or withdrawal due to an adverse event.4
DELZICOL® (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in patients 5 years of age and older and for the maintenance of remission of UC in adults.
DELZICOL® (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in patients 5 years of age and older and for the maintenance of remission of UC in adults.
Please see full Prescribing Information for DELZICOL.
DELZICOL® (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in patients 5 years of age and older and for the maintenance of remission of UC in adults.
DELZICOL® (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in patients 5 years of age and older and for the maintenance of remission of UC in adults.
Please see full Prescribing Information for DELZICOL.
References: